Topic

Texas

A collection of 386 issues

The Requirements Checklist to Get Brineura (Cerliponase Alfa) Covered by Blue Cross Blue Shield in Texas

Answer Box: Getting Brineura Covered in Texas Blue Cross Blue Shield of Texas requires prior authorization for Brineura (cerliponase alfa) with strict clinical criteria including confirmed CLN2 diagnosis, specialized neurologist prescription, and documented ambulatory function. Submit via their medical PA portal with genetic/enzyme testing, baseline CLN2 scores, and medical
5 min read

How to Get Tegsedi (inotersen) Covered by UnitedHealthcare in Texas: Complete Prior Authorization Guide with Forms and Appeals

Answer Box: Getting Tegsedi (inotersen) Approved by UnitedHealthcare in Texas Quick Path to Coverage: UnitedHealthcare requires prior authorization for Tegsedi (inotersen) for hereditary transthyretin amyloidosis with polyneuropathy. You'll need: (1) confirmed hATTR diagnosis with TTR mutation, (2) REMS program enrollment for patient, prescriber, and pharmacy, and (3) baseline
6 min read

Getting StrataGraft Covered by UnitedHealthcare in Texas: Prior Authorization Guide, Appeals Process, and Alternative Options

Answer Box: Getting StrataGraft Covered in Texas StrataGraft requires prior authorization from UnitedHealthcare as a medical benefit (not pharmacy). Submit PA through the UHC Provider Portal with burn depth documentation, TBSA calculations, and clinical justification that autografting would otherwise be needed. Standard decisions take 5-15 business days; expedited reviews (24-72
6 min read

How to Get Kanuma (Sebelipase Alfa) Covered by UnitedHealthcare in Texas: Complete Prior Authorization and Appeals Guide

Quick Answer: Getting Kanuma Approved by UnitedHealthcare in Texas Kanuma (sebelipase alfa) requires prior authorization from UnitedHealthcare/OptumRx for lysosomal acid lipase deficiency (LAL-D). Success depends on: confirmed LAL-D diagnosis (enzyme assay or genetic testing), documented disease severity (elevated liver enzymes, dyslipidemia), and evidence that supportive therapies are insufficient. First
5 min read